Tesamorelin
Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.6/10.
Tesamorelin scored 5.6 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
What It Is
Tesamorelin is a prescription peptide that mimics growth hormone-releasing hormone and stimulates the pituitary GHRH receptor. Instead of injecting growth hormone directly, tesamorelin amplifies endogenous pulsatile GH release and raises downstream IGF-1. The practical result is a selective lipolytic signal that reduces visceral adipose tissue in the FDA-approved HIV lipodystrophy population while largely preserving subcutaneous fat.
The clearest clinical use is excess abdominal fat in adults with HIV-associated lipodystrophy. Falutz 2007 is the landmark Phase 3 trial behind approval, and the current FDA 2025 label keeps the indication narrow: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, not weight loss. The DHHS/NIH HIV guidelines also describe tesamorelin as the only US FDA-approved therapy for excessive abdominal fat in people with HIV, while warning that effects reverse after stopping.
Off-label interest comes from three adjacent signals. First, tesamorelin improves visceral-fat and metabolic markers in responders, as summarized by Stanley 2012. Second, HIV-associated fatty-liver data from Stanley 2019 and hepatic transcriptomic work from Fourman 2020 suggest a liver-fat and fibrosis-pathway role. Third, cognition data from Baker 2012 created interest in GH-axis restoration for older adults and MCI, though Ellis 2025 tempers the neurocognitive enthusiasm in HIV. A 2026 meta-analysis by Badran 2026 reinforces the body-composition and hepatic-fat direction but does not remove the core limitation: tesamorelin is expensive, injectable, reversible, contraindicated in key groups, and WADA-prohibited in sport.
Terminology
For the regulatory baseline, see the FDA prescribing label.
- GHRH: Growth hormone-releasing hormone. A hypothalamic peptide that tells the pituitary to release growth hormone in pulses.
- GHRH analog: A synthetic peptide that mimics GHRH. Tesamorelin is stabilized so it lasts longer than native GHRH.
- GH: Growth hormone. A pituitary hormone involved in growth, lipolysis, repair, and metabolism.
- IGF-1: Insulin-like growth factor 1. A downstream hormone used as the main blood marker of GH-axis activity.
- GHRHR: Growth hormone-releasing hormone receptor. The pituitary receptor tesamorelin stimulates.
- VAT: Visceral adipose tissue. Deep abdominal fat around organs, strongly tied to cardiometabolic risk.
- SAT: Subcutaneous adipose tissue. Fat under the skin, generally preserved during tesamorelin therapy.
- Lipodystrophy: Abnormal fat distribution. HIV-associated lipodystrophy often combines central fat gain with peripheral fat changes.
- NAFLD / MASLD: Fatty liver disease not primarily driven by alcohol. MASLD is the newer metabolic-dysfunction terminology.
- MASH: Metabolic dysfunction-associated steatohepatitis, the newer term replacing NASH.
- HbA1c: A roughly 3-month blood-glucose exposure marker. Tesamorelin can modestly worsen glucose markers in susceptible users.
- IGF-1 monitoring: Periodic blood testing to keep IGF-1 within the age-adjusted reference range.
- 503A / 503B compounding: US pharmacy compounding pathways. Tesamorelin has an approved commercial product, so routine low-cost compounding is not the same as approved Egrifta SV.
- DPP-IV: Dipeptidyl peptidase-4, an enzyme that rapidly degrades native GHRH. Tesamorelin is modified to resist this breakdown.
- WADA: World Anti-Doping Agency. WADA prohibits tesamorelin at all times because it is a growth hormone-releasing factor.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection (brand Egrifta SV) | Lyophilized powder reconstituted with sterile water, single-use vial | 2 mg daily FDA-approved protocol for HIV-associated lipodystrophy. Abdominal injection preferred with site rotation. | 1 mg to 2 mg daily Off-label VAT, NAFLD, and metabolic-health use generally follows label timing but often starts below label dose. |
| Subcutaneous injection (non-approved compounded or research supply) | Lyophilized powder reconstituted with bacteriostatic water, multi-use vial | Not applicable in the US because the approved commercial product limits routine compounding pathways FDA-approved tesamorelin exists commercially. Off-label clinic or research-peptide supply is outside the approval package. | 1 mg to 4 mg daily Used by some biohackers for cost reasons. Quality varies by supplier and independent sterility/endotoxin verification is often absent. |
Protocols
HIV-associated lipodystrophy (FDA-approved) Clinical
- Dose
- 2 mg subcutaneous daily in the evening
- Frequency
- Daily
- Duration
- Continuous; pivotal trials evaluated 26 weeks with safety-extension data through 52 weeks
[Falutz 2007](https://pubmed.ncbi.nlm.nih.gov/18057338/) supports VAT reduction over 26 weeks; [Falutz 2010](https://pubmed.ncbi.nlm.nih.gov/20101189/) supports the safety-extension pattern. Benefits regress after stopping.
HIV-associated NAFLD / MASLD specialist protocol Clinical
- Dose
- 2 mg subcutaneous daily
- Frequency
- Daily
- Duration
- 12 months in the main HIV-NAFLD randomized trial
[Stanley 2019](https://pubmed.ncbi.nlm.nih.gov/31611038/) tested HIV-associated NAFLD over 12 months. Use requires liver imaging, glucose monitoring, and specialist oversight.
Cognitive aging / MCI research protocol Clinical
- Dose
- 1 mg subcutaneous daily before bedtime
- Frequency
- Daily
- Duration
- 20 weeks
[Baker 2012](https://pubmed.ncbi.nlm.nih.gov/22869065/) used a GHRH analog protocol in older adults and MCI. Cognitive use remains research-grade, not an FDA-approved indication.
Off-label VAT / longevity-oriented biohacker protocol Mixed
- Dose
- 1 mg subcutaneous nightly
- Frequency
- Daily or 5 days on / 2 days off
- Duration
- 8 to 16 weeks for short cycles; 6 to 12 months for imaging-confirmed VAT or liver-fat goals
Lower-dose use is common but not equivalent to the approval evidence. Monitor IGF-1, fasting glucose, HbA1c, edema, arthralgia, and injection reactions.
Stacked GHRH + GHRP protocol Anecdotal
- Dose
- Tesamorelin 1 mg plus ipamorelin 200 to 300 mcg before bed
- Frequency
- Daily or cyclic
- Duration
- 8 to 16 weeks
Mechanistically targets GHRH and ghrelin/GHRP pathways. No RCTs validate stacked dosing. Stacking with CJC-1295 is usually redundant because both stimulate the GHRH receptor.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.73
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.0 | 1.000 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 4.5 | 1.125 | |
| Speed of Onset | 10% | 2.5 | 0.250 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 4.0 | 0.600 | |
| Total | 3.725 |
Upside Rationale
Tesamorelin has its strongest upside when the reader wants body composition, hormonal, metabolic health and can use the intervention in the studied context. Badran et al. 2026 gives the score a real evidence anchor, while Russo et al. 2024 helps define where the effect is narrower or broader. The practical value is not magic; it is a specific lever that can matter when HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight already point in the right direction. The upside is strongest when the mechanism, population, and outcome line up instead of borrowing confidence from neighboring claims. In practice, the intervention belongs in a stack only after higher-use basics are already stable.
Efficacy (4.0/5.0). Tesamorelin has a rare peptide-category advantage: objective imaging endpoints in randomized trials. Falutz 2007 showed reduced VAT versus placebo in adults with HIV and abdominal fat accumulation, with lipid and body-image improvements and increased IGF-1. Falutz 2010 supports the safety-extension pattern, including the reality that effects fade after stopping. For liver fat, Stanley 2019 and Fourman 2020 extend the signal into HIV-associated NAFLD. The score stays at 4.0 rather than higher because benefits are conditional, chronic, expensive, and strongest in high-VAT or HIV-defined phenotypes.
Breadth of benefits (4.0/5.0). Tesamorelin touches several systems downstream of one endocrine lever. The core body-composition signal is VAT reduction. The metabolic signal includes triglyceride and glucose-pattern differences in responders, with Stanley 2012 linking VAT response to better metabolic profiles. The hepatic signal includes liver-fat reduction and transcriptomic changes. The cognition signal comes from GHRH analog treatment in older adults via Baker 2012, but Ellis 2025 makes the brain case less clean in HIV. Muscle quality, adipose quality, inflammation, and body-image measures add breadth without turning tesamorelin into a general longevity drug.
Evidence quality (4.5/5.0). Tesamorelin evidence quality is high for the approved HIV lipodystrophy indication and moderate for off-label extrapolations. The approval package includes Phase 3 randomized data and extension studies; Badran 2026 adds a five-RCT meta-analysis confirming the general body-composition and hepatic-fat direction. The Cochrane page is withdrawn, so there is no active Cochrane endorsement. The FDA and NIH authority signals are strong for HIV-associated abdominal fat, but long-term cardiovascular outcomes, general obesity use, general-population MASH, and cognitive protection remain authority gaps.
Speed of onset (2.5/5.0). Tesamorelin is slow where it matters. IGF-1 can rise quickly after initiation, but visible body-composition change usually needs weeks and imaging-confirmed VAT reduction is assessed over 13 to 26 weeks. Stanley 2019 used a 12-month liver-fat frame, which is a realistic timeline for hepatic outcomes. Cognitive trials such as Baker 2012 used a 20-week intervention period. Subjective sleep changes can appear earlier, including Nick's report of deeper sleep, but the measurable endpoints that justify tesamorelin are multi-month outcomes.
Durability (1.5/5.0). Tesamorelin benefits are not durable after discontinuation. The DHHS/NIH HIV guidelines explicitly note that VAT reductions reverse after stopping, and the extension literature supports that pattern. This is the central weakness of the intervention. Tesamorelin amplifies an endocrine signal while the drug is present; it does not permanently reset adipose biology, liver-fat tendency, or GH-axis aging. For HIV lipodystrophy or NAFLD, realistic planning looks like chronic therapy, repeated cycles with monitoring, or a bridge to maintenance interventions.
Bioindividuality (4.0/5.0). Tesamorelin is highly phenotype-dependent, which is good when selection is done properly and disappointing when it is not. Best responders have high baseline VAT, HIV-associated lipodystrophy, HIV-associated fatty liver, or low-normal IGF-1 with age-related complaints. Lake 2021 reinforces that responder biology can include adipose-quality changes, not just smaller fat depots. Low-VAT healthy adults, athletes chasing marginal aesthetics, and people with normal IGF-1 have less room to benefit. Glucose risk, retinopathy status, malignancy history, pregnancy status, cost tolerance, and needle tolerance all materially change the net value.
Downside contribution: 3.17 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.5 | 0.750 | |
| Side Effect Profile | 15% | 2.5 | 0.375 | |
| Financial Cost | 5% | 4.5 | 0.225 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 2.0 | 0.300 | |
| Reversibility | 25% | 2.0 | 0.500 | |
| Total | 2.400 | |||
| Harm subtotal × 1.4 | 2.695 | |||
| Opportunity subtotal × 1.0 | 0.475 | |||
| Combined downside | 3.170 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.830 |
Downside Rationale
Tesamorelin still needs caution because the downside profile depends on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight, not only on the headline benefit. Safety, cost, and effort scores sit at 2.5, 4.5, and 2.5 out of 5, which means the tradeoff changes by user type. Badran et al. 2026 supports the core benefit, but the same evidence base leaves gaps around long-term use, nonresponders, and people outside the studied population. The downside is not only adverse events; it is also cost, effort, sourcing quality, contraindications, and the chance of chasing the wrong lever. That makes screening and expectation-setting part of the intervention, not an optional afterthought.
Safety risk (2.5/5.0). Tesamorelin is safer than continuous exogenous HGH in concept, but it is still a prescription endocrine drug with serious screening requirements. The FDA 2025 label lists contraindications including active malignancy, pregnancy, hypothalamic-pituitary disruption, hypersensitivity, and warnings for neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity, injection reactions, and acute critical illness. Long-term cardiovascular safety has not been established. The risk is manageable with clinician oversight, but cancer history, diabetic retinopathy, uncontrolled diabetes, and pregnancy shift tesamorelin from "worth considering" to inappropriate.
Side effect profile (2.5/5.0). Tesamorelin side effects are common enough to matter but usually not severe enough to dominate the score. Falutz 2007 reported more adverse-event withdrawals with tesamorelin than placebo, and the broader trial literature consistently points to arthralgia, myalgia, paresthesia, edema, and injection-site reactions. Badran 2026 also lists these tolerability issues in the meta-analysis preview. Glucose intolerance is the practical lab concern, especially in prediabetes. Users who start lower than label dose often report smoother tolerability, but lower-dose off-label protocols do not erase the need for monitoring.
Financial cost (4.5/5.0). Tesamorelin is one of the most financially restrictive outpatient peptide interventions. Brand Egrifta SV can run several thousand dollars per month without coverage, and insurance is usually tied to documented HIV-associated lipodystrophy with prior authorization. That cost competes with DEXA or MRI tracking, CGM use, medical visits, GLP-1 therapy, resistance training support, nutrition coaching, rapamycin-style longevity monitoring, and other higher-confidence investments. Cheap non-approved peptide supply changes the sticker price but introduces identity, sterility, and endotoxin uncertainty. The cost score stays severe because the evidence-aligned route is expensive.
Time / effort burden (2.5/5.0). Tesamorelin requires daily subcutaneous injection, reconstitution, site rotation, cold-chain awareness depending on product handling, sharps disposal, and periodic lab monitoring. The injection itself is quick, often around a few minutes, but the friction compounds over months. Timing is usually evening or pre-bed to align with nocturnal GH physiology. For needle-averse users or frequent travelers, this is a real burden. Compared with oral supplements, tesamorelin is high effort; compared with complex infusion therapies, it is manageable. The middle score reflects that daily adherence is feasible but not casual.
Opportunity cost (2.5/5.0). Tesamorelin crowds out other GH-axis and metabolic interventions because the cost and mechanism are both concentrated. Stacking with CJC-1295 is typically redundant because both target the GHRH side of GH release. Combining with ipamorelin or other GHRP approaches is more coherent but remains unvalidated. For many users, the same budget could fund GLP-1 therapy, personal training, liver imaging, sleep apnea treatment, CGM-guided nutrition, or cardiometabolic basics. Tesamorelin stacks cleanly with lifestyle work, but its price and chronic nature create meaningful opportunity cost.
Dependency / withdrawal (2.0/5.0). Tesamorelin does not create addiction, intoxication, or classic withdrawal, but it creates functional dependence if the goal is maintaining VAT or liver-fat reduction. The DHHS/NIH guideline discussion notes reversal after discontinuation, which is the practical dependency problem. Stop tesamorelin and the amplified GH/IGF-1 signal returns toward baseline; fat distribution can follow. There is no good evidence of permanent pituitary damage at label dosing, but repeated cycles without maintenance habits can become a costly loop.
Reversibility (2.0/5.0). Tesamorelin is mostly reversible, which is both a safety advantage and an efficacy weakness. VAT reduction, liver-fat improvement, IGF-1 elevation, and subjective changes generally fade after stopping rather than persisting as permanent remodeling. That makes discontinuation cleaner than surgery, implants, or irreversible tissue procedures. It also means the intervention does not "bank" much durable benefit unless the user uses the improved window to build training, nutrition, sleep, and metabolic maintenance. Reversibility is therefore scored as mild-to-moderate downside rather than minimal downside.
Verdict
Tesamorelin is a 5.6/10 fit for body composition, hormonal, metabolic health, especially for readers who can match the protocol to HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. The best evidence anchors are Badran et al. 2026, which Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass, and Russo et al. 2024, which INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold. Tesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for hepatic fat reduction, but cost, daily injections, reversibility, cancer contraindications, and anti-doping prohibition keep the score at 6.6/10.
✅ Best for: Adults with HIV-associated abdominal lipodystrophy who fit the FDA-labeled indication and can access prescription Egrifta SV with clinician monitoring. Tesamorelin is also worth discussing for HIV-associated NAFLD or early MASH under hepatology or infectious-disease supervision, especially when liver fat is imaging-confirmed. Select older adults or MCI patients with low-normal IGF-1 may reasonably track the cognitive research, but cognition should remain secondary. Best-case users monitor IGF-1, HbA1c, fasting glucose, edema, arthralgia, retinopathy risk, and cancer history while using tesamorelin as part of a broader body composition and metabolic health plan.
❌ Avoid if: Avoid tesamorelin with active malignancy, prior malignancy without oncology clearance, pregnancy, trying to conceive, hypothalamic-pituitary disruption, severe or active diabetic retinopathy, poorly controlled diabetes, acute critical illness, or prior hypersensitivity to tesamorelin or mannitol. Competitive athletes should avoid tesamorelin because WADA prohibits growth hormone-releasing factors at all times. Also avoid tesamorelin if the goal is casual weight loss, rapid aesthetics, unmonitored longevity experimentation, or cheap gray-market peptide use. If you cannot commit to daily injections, lab monitoring, and months-long tracking, a lower-friction sleep or metabolic intervention is a better first move.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Body Composition / Fat Loss: 7.5/10
Score: 7.5/10Tesamorelin scores 7.5/10 for body composition, with the best signal coming from Badran et al. 2026. Phase 3 HIV lipodystrophy evidence supports the strongest body-composition signal: Falutz 2007 showed VAT reduction with subcutaneous fat largely preserved, and Stanley 2012 linked responder VAT loss to improved metabolic markers. The score stays bounded because Tesamorelin evidence for body composition can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Hormonal / Endocrine: 7.5/10
Score: 7.5/10For hormonal, Tesamorelin lands at 7.5/10 because Russo et al. 2024 supports the core mechanism. Tesamorelin directly stimulates the GHRH receptor and raises IGF-1 through a feedback-intact pituitary pathway. Falutz 2007 supports the GH/IGF-1 axis effect in the pivotal HIV lipodystrophy population. The score stays bounded because Tesamorelin evidence for hormonal can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Metabolic Health: 7.0/10
Score: 7.0/10The metabolic health use case earns 7.0/10 for Tesamorelin, anchored by Ellis et al. 2025. Tesamorelin reduces VAT and triglyceride-related risk markers, but glucose effects are mixed. Stanley 2012 found VAT responders had better lipid and glucose patterns than nonresponders, while FDA labeling still warns about glucose intolerance. The score stays bounded because Tesamorelin evidence for metabolic health can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Liver / Detoxification: 6.5/10
Score: 6.5/10Evidence puts Tesamorelin at 6.5/10 for liver detox, mainly through Falutz et al. 2007. HIV-associated fatty liver data support a meaningful liver-fat signal. Stanley 2019 tested tesamorelin in HIV-associated NAFLD, and Fourman 2020 reported hepatic transcriptomic changes consistent with less inflammatory and fibrotic signaling. The score stays bounded because Tesamorelin evidence for liver detox can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cognition / Focus: 6.5/10
Score: 6.5/10Cognition Focus is a 6.5/10 fit for Tesamorelin, based on the evidence summarized in Falutz et al. 2008. The cognition signal comes mainly from Baker 2012, which reported improved cognitive function in older adults after GHRH analog treatment. A 2025 HIV neurocognition trial was smaller and did not show a clear neurocognitive advantage. The score stays bounded because Tesamorelin evidence for cognition focus can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Cardiovascular: 6.0/10
Score: 6.0/10The practical cardiovascular read is 6.0/10 for Tesamorelin, with Falutz et al. 2010 setting the ceiling. Tesamorelin improves some cardiometabolic risk surrogates through VAT reduction, triglyceride changes, inflammatory-marker shifts, and possibly carotid or adipose-quality pathways. Stanley 2011 supports inflammatory-marker improvement tied to VAT response. The score stays bounded because Tesamorelin evidence for cardiovascular can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Geriatric / Aging Population: 6.0/10
Score: 6.0/10Tesamorelin reaches 6.0/10 for geriatric when the goal matches the population in Stanley et al. 2011. Tesamorelin targets an age-sensitive GH/IGF-1 axis and may improve VAT, cognition, and muscle quality in select older adults, but the geriatric case is conditional. Adrian 2019 supports exploratory muscle-quality changes in HIV responders. The score stays bounded because Tesamorelin evidence for geriatric can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Memory: 5.5/10
Score: 5.5/10A 5.5/10 memory rating fits Tesamorelin, since Stanley et al. 2012 points to a real but bounded effect. Baker 2012 reported memory-related improvement after GHRH analog therapy in older adults and MCI. The score stays moderate because replication and disease-specific neurodegeneration outcomes remain limited. The score stays bounded because Tesamorelin evidence for memory can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Neuroprotection: 5.5/10
Score: 5.5/10For readers tracking neuroprotection, Tesamorelin deserves 5.5/10 because Stanley et al. 2014 gives the strongest anchor. GH/IGF-1 signaling supports neuronal survival and synaptic function, and Baker 2012 gives human cognitive signal. Direct neuroprotection outcomes, dementia delay, and structural brain endpoints remain unproven for tesamorelin. The score stays bounded because Tesamorelin evidence for neuroprotection can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Healthspan: 5.5/10
Score: 5.5/10The evidence-weighted call is 5.5/10 for Tesamorelin in healthspan, led by Stanley et al. 2019. Tesamorelin improves VAT, liver fat, and selected metabolic markers in high-risk groups, which may support healthspan. The score stays capped because GH/IGF-1 signaling has complex aging biology and no lifespan or hard healthspan outcome trials. The score stays bounded because Tesamorelin evidence for healthspan can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
Anti-Inflammatory: 5.0/10
Score: 5.0/10Tesamorelin has a 5.0/10 anti inflammatory case because Fourman et al. 2020 supports a plausible benefit. Stanley 2011 reported inflammatory-marker changes that tracked with visceral-fat reduction, and Fourman 2020 showed downregulation of hepatic inflammatory gene sets in HIV-associated NAFLD. The score stays bounded because Tesamorelin evidence for anti inflammatory can depend on HIV lipodystrophy context, IGF-1 monitoring, glucose risk, and prescription oversight. In practice, the useful question is whether this intervention changes the tracked outcome enough to justify the cost, effort, and risk profile.
| Use Case | Score | Summary |
|---|---|---|
| ○ Sleep Quality | 4.5 | Nick's personal review reports deeper sleep, and bedtime dosing matches nocturnal GH physiology. Controlled tesamorelin polysomnography evidence is absent, so this stays an experiential and mechanistic subrating rather than a clinical sleep claim. |
| ○ Muscle Growth / Hypertrophy | 4.5 | GH/IGF-1 signaling can support lean tissue, and Adrian 2019 found increased trunk muscle area and density in HIV tesamorelin responders. Strength transfer and direct hypertrophy outcomes remain modest. |
| ○ Recovery / Repair | 4.5 | Tesamorelin raises an anabolic repair axis through GH and IGF-1, but recovery-specific tesamorelin trials are lacking. The score reflects indirect endocrine support, not proven recovery acceleration in athletes or injury populations. |
| ○ Strength / Power | 4.0 | Tesamorelin may improve lean tissue quality in responders, as in Adrian 2019, but lean mass or muscle-density changes do not automatically translate into maximal strength or power output. |
| ○ Neuroplasticity | 4.0 | IGF-1 supports synaptic plasticity and brain repair pathways, and Baker 2012 gives a human cognition signal. Direct tesamorelin neuroplasticity biomarkers remain sparse. |
| ○ Energy / Fatigue | 4.0 | Improved VAT, sleep quality, and metabolic markers may improve subjective energy in selected users. Tesamorelin has no stimulant mechanism, and energy outcomes were not primary endpoints in the pivotal evidence. |
| ○ Sleep Architecture (Deep/REM) | 4.0 | Bedtime dosing tries to amplify the natural slow-wave-sleep GH pulse. The timing logic is coherent, but controlled sleep-architecture endpoints with tesamorelin have not established a robust clinical effect. |
| ○ Longevity / Lifespan | 4.0 | Longevity scoring remains cautious because GH/IGF-1 biology cuts both ways: metabolic improvements may help high-VAT adults, while higher IGF-1 can raise theoretical cancer-growth concern in susceptible users. |
| ○ Injury Recovery | 3.5 | GH/IGF-1 supports connective tissue and soft-tissue repair generally, but there are no tesamorelin-specific injury-recovery trials. The score reflects endocrine plausibility and indirect evidence only. |
| ○ Circadian Rhythm / Chronobiology | 3.5 | Evening tesamorelin dosing aligns with nocturnal GH secretion, but tesamorelin is not a circadian-reset intervention. Any circadian benefit is secondary to sleep timing and endocrine pulse matching. |
| ○ Blood Sugar / Glycemic Control | 3.5 | Tesamorelin can modestly worsen glucose tolerance in susceptible users despite VAT benefits. FDA labeling warns about glucose intolerance and diabetes monitoring, so blood-sugar scoring remains intentionally conservative. |
| ○ Bone / Joint Health | 3.5 | GH/IGF-1 signaling supports bone remodeling, but tesamorelin trials did not establish DEXA bone-density improvement or joint-specific benefit. Arthralgia is also a known tolerability issue. |
| ○ Wound Healing | 3.0 | GH can support tissue repair, but tesamorelin-specific wound-healing trials are absent. This rating remains low-moderate because the intervention is not clinically established for wounds. |
| ○ Skin / Beauty | 3.0 | GH/IGF-1 can influence dermal thickness and collagen turnover, but tesamorelin has no strong skin-aging RCT evidence. Any skin benefit is indirect and should not drive use. |
| ○ Mood / Emotional Regulation | 3.0 | Body-image and quality-of-life improvements appear in HIV lipodystrophy evidence, but tesamorelin is not a mood treatment. Mood benefit is most likely secondary to body composition, sleep, or metabolic improvements. |
| ○ Libido / Sexual Health | 3.0 | GH restoration may indirectly support sexual function in deficient or metabolically impaired adults, but tesamorelin has no direct libido trial evidence. The score stays exploratory. |
| ○ Traumatic Brain Injury | 3.0 | Post-TBI pituitary dysfunction can involve GH deficiency, but tesamorelin itself has not been tested as a TBI therapy. Endocrine evaluation matters more than unsupervised peptide use. |
| ○ Mitochondrial | 3.0 | Fourman 2020 reported hepatic oxidative-phosphorylation gene changes in HIV-associated NAFLD, but tesamorelin is not a direct mitochondrial therapy. The mitochondrial score remains indirect. |
Frequently Asked Questions
How does tesamorelin differ from taking growth hormone directly?
Tesamorelin stimulates your pituitary's own GH pulse instead of replacing growth hormone directly. Falutz 2007 showed IGF-1 elevation and VAT reduction through this GHRH analog pathway. Exogenous HGH bypasses pituitary feedback and can create more continuous exposure. That does not make tesamorelin risk-free: active malignancy, pregnancy, hypothalamic-pituitary disruption, glucose intolerance, and elevated IGF-1 monitoring still matter.
What is the actual dose for biohacker use vs the FDA label?
The FDA-labeled dose is 2 mg subcutaneous daily for HIV-associated lipodystrophy. Off-label biohacker protocols often use 1 mg at night, sometimes 5 days on and 2 days off, but that lower-dose cycling is not the pivotal-trial protocol. Higher 3 to 4 mg/day community dosing exceeds the evidence base and likely increases edema, arthralgia, paresthesia, injection reactions, and glucose risk without proven added benefit.
What does the visceral fat evidence actually show?
Tesamorelin has the strongest evidence for reducing visceral adipose tissue in HIV-associated lipodystrophy. Falutz 2007 is the landmark Phase 3 trial, and Falutz 2010 supports the extension pattern. Subcutaneous fat is generally preserved, which distinguishes tesamorelin from simple calorie restriction. The drawback: benefits fade after discontinuation, so long-term use or a maintenance bridge is usually needed.
Does tesamorelin help liver fat and NAFLD?
Tesamorelin has promising HIV-associated NAFLD evidence, but it is not a general-population MASH drug. Stanley 2019 tested tesamorelin for HIV-associated NAFLD over 12 months, and Fourman 2020 found hepatic transcriptomic changes tied to oxidative phosphorylation, inflammation, and fibrosis pathways. General MASH histology outcomes still need larger confirmation outside the HIV subgroup.
What does the cognition and brain data look like?
The cognition signal is real but not settled. Baker 2012 reported cognitive improvement in older adults after GHRH analog treatment, including people with MCI. Ellis 2025 was a smaller HIV neurocognition trial and did not show a clear neurocognitive advantage over standard care. Treat cognition as an investigational use, especially if baseline IGF-1 is already normal.
Is tesamorelin safer than exogenous HGH long-term?
Tesamorelin is probably cleaner than exogenous HGH mechanistically, but long-term safety is not unlimited. The FDA label lists active malignancy and pregnancy as contraindications and warns about neoplasms, elevated IGF-1, glucose intolerance, fluid retention, hypersensitivity, injection-site reactions, and acute critical illness. Long-term cardiovascular safety has not been established, so monitoring matters.
How does compounded tesamorelin compare to brand Egrifta for cost and quality?
Brand Egrifta SV is the evidence-aligned supply route, but cost is the major barrier. Non-approved compounded or research-peptide tesamorelin can be much cheaper, yet identity, sterility, and endotoxin testing are not equivalent to an FDA-approved product. That risk belongs to sourcing, not the molecule itself. For prescription use, start with the approved route and insurance documentation before considering anything else.
How should tesamorelin be timed and stacked with other peptides?
Evening injection is the usual timing because endogenous GH secretion peaks during slow-wave sleep. Stacking tesamorelin with CJC-1295 is usually redundant because both stimulate the GHRH receptor. A tesamorelin plus ipamorelin-style stack is more coherent mechanistically because it combines GHRH and ghrelin/GHRP signaling, but no RCT validates stacked peptide dosing. Keep stacking experimental and monitor IGF-1 and glucose.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Phase 3 MASH trial positive on histologic endpoints | Efficacy 4.0 to 4.5; Evidence 4.5 to 5.0; Breadth 4.0 to 4.5 | 6.5 / 10 💪 Strong recommend |
| Phase 3 cognitive or MCI trial confirms the GHRH cognition signal | Efficacy 4.0 to 4.5; Evidence 4.5 to 5.0 | 6.2 / 10 👍 Worth trying |
| Long-term cancer incidence signal appears in post-market surveillance | Safety 2.5 to 4.0 | 4.4 / 10 ⚖️ Neutral |
| Generic tesamorelin approval brings cost under $500/month | Cost 4.5 to 2.5 | 6.4 / 10 💪 Strong recommend |
| FDA allows 503A compounding during supply disruption with verified quality controls | Cost 4.5 to 3.0 | 6.2 / 10 👍 Worth trying |
| Independent replication plus cardiovascular outcomes data confirms lower event risk | Evidence 4.5 to 5.0; Breadth 4.0 to 4.5 | 6.3 / 10 👍 Worth trying |
Key Evidence Sources
- Badran et al. 2026 - Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials, Obesity Research & Clinical Practice. Meta-analysis of 5 RCTs; found reductions in VAT, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with increased lean body mass.
- Russo et al. 2024 - Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS. INSTI-regimen subgroup analysis; reductions in visceral fat, hepatic fat fraction, and trunk-to-appendicular fat ratio; below Track 1 size threshold.
- Ellis et al. 2025 - Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity, Journal of Infectious Diseases. Open-label randomized phase 2 trial; waist circumference improved, but neurocognitive benefit did not significantly differ from standard care.
- Falutz et al. 2007 - Metabolic effects of a growth hormone-releasing factor in patients with HIV, New England Journal of Medicine. Landmark Phase 3 trial; reduced VAT, improved lipid/body-image measures, increased IGF-1, and had more adverse-event withdrawals than placebo.
- Falutz et al. 2008 - Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation, AIDS. Longer-term HIV abdominal-fat accumulation data supporting sustained treatment effect and safety monitoring.
- Falutz et al. 2010 - Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: randomized placebo-controlled trial with safety extension, JAIDS. Randomized placebo-controlled trial plus safety extension; supports VAT reduction and regression after discontinuation.
- Stanley et al. 2011 - Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat, AIDS. 410 HIV-infected patients; inflammatory and fibrinolytic marker changes related to VAT reduction.
- Stanley et al. 2012 - Reduction in Visceral Adiposity Is Associated With an Improved Metabolic Profile in HIV-Infected Patients Receiving Tesamorelin, Clinical Infectious Diseases. Pooled responder analysis; VAT responders had better triglyceride and glucose-marker patterns than nonresponders.
- Stanley et al. 2014 - Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial, JAMA. 50-person RCT; tesamorelin reduced visceral fat and liver fat over 6 months in HIV abdominal-fat accumulation.
- Stanley et al. 2019 - Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: randomized, double-blind, multicentre trial, Lancet HIV. 61-person HIV-associated NAFLD trial; reduced liver fat and informed later hepatic transcriptomic analyses.
- Fourman et al. 2020 - Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD, JCI Insight. Mechanistic follow-up using paired liver biopsy specimens; showed changes in oxidative phosphorylation, inflammatory, tissue-repair, and fibrosis-related gene pathways.
- Lake et al. 2021 - Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity, Journal of Clinical Endocrinology & Metabolism. Secondary analysis showing improved VAT and SAT density independent of fat-quantity changes among responders.
- Adrian et al. 2019 - The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV, Journal of Frailty & Aging. Exploratory secondary analysis; tesamorelin responders had improved trunk muscle area and density versus placebo.
- Baker et al. 2012 - Growth hormone-releasing hormone improves cognitive function in adults with mild cognitive impairment and healthy older adults, Archives of Neurology. 20-week cognition RCT of GHRH analog therapy in older adults and MCI; supports but does not settle cognitive use.
- FDA 2025 - EGRIFTA WR prescribing label. Current FDA labeling: indication, limitations, contraindications, warnings, and dosing.
- DHHS/NIH 2025 - Weight Gain in People With HIV, Adult and Adolescent ART Guidelines. Guideline mentions tesamorelin as the only US FDA-approved therapy for excessive abdominal fat in people with HIV and notes reversal after discontinuation.
- Cochrane 2013 withdrawn review page - Treatment of lipodystrophy in patients with HIV infection. Cochrane page exists but the review is withdrawn; no active Cochrane tesamorelin position located in the audit.
- WADA 2026 - Prohibited List, growth hormone-releasing factors. Tesamorelin is listed under growth hormone-releasing factors and prohibited at all times in sport.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: High
Citations: Falutz 2007, Falutz 2010, Stanley 2011, Stanley 2012, Stanley 2019, Fourman 2020, Russo 2024, Ellis 2025, Badran 2026, FDA 2025
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Egrifta FDA approval 2010, Egrifta SV reformulation 2018, DHHS HIV Guidelines 2025
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for Tesamorelin
The lenses mostly diverge rather than converge. Modern evidence supports tesamorelin for a narrow, clinically defined metabolic phenotype, with meaningful off-label signals for HIV-associated NAFLD and weaker cognition data. Historical evidence explains why the drug exists: HIV lipodystrophy created a specific unmet need that diet and exercise often did not solve. Traditional evidence is effectively absent. Honest synthesis: tesamorelin belongs in monitored medical or advanced biohacker contexts where VAT, liver fat, IGF-1, glucose, and contraindications are measured, not in casual wellness stacks.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- IGF 1 Baseline (pre-protocol) During | Expected Up
- Fasting Glucose During | Expected Watch
- HbA1c Post | Expected Watch
- ALT During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Sleep During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Abdominal Fullness Scale 1-5 | During | Expected Down
- Water Retention Scale 1-5 | During | Expected Watch
- Joint Stiffness Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Severe edema or carpal tunnel symptoms
- Fasting glucose drift upward
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.725 − 1.830 = 0.895
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.895 / 5) × 5 = 5.9 / 10
